Follow-up procedures for non-muscle-invasive bladder cancer: An update

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1229-1241

  Anastasiadis, Anastasios ^a   Cordeiro, Ernesto ^a   Bus, Mieke Tj ^a   Alivizatos, Gerasimos ^b   De La Rosette, Jean J M C H ^a   De Reijke, Theo M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

bladder neoplasm; cystoscopy; individualization; surveillance; ultrasonography; urine cytology; urine marker

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER;

BLADDER CARCINOMA; BLADDER MUCOSA; BLADDER TUMOR; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CARCINOMA IN SITU; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOFLUORESCENCE TEST; MASS SPECTROMETRY; MICROSATELLITE MARKER; MOLECULARLY TARGETED THERAPY; PATIENT CODING; RECURRENCE RISK; REVIEW; SUBMUCOSA; TREATMENT INDICATION; URINE CYTOLOGY;

CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTOSCOPY; CYTODIAGNOSIS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; IMMUNOASSAY; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; MONITORING, PHYSIOLOGIC; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84867949525     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.98     Document Type: Review

References (89)

1. Soloway MS. It is time to abandon the 'superficial' in bladder cancer. Eur. Urol. 52(6), 1564-1565 (2007). (Pubitemid 350052416)
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J. Urol. 27(3), 289-293 (2009).
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
4. Lee CS, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int. 102(9 Pt B), 1228-1233 (2008).
5. Schmitz-Dräger BJ. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur. Urol. 60(4), 721-723 (2011).
6. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003). (Pubitemid 38041357)
7. Tilki D, Burger M, Dalbagni G et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 60(3), 484-492 (2011).
8. Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 56(5), 793-797 (2000).
9. Larsson P, Wijkström H, Thorstenson A et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand. J. Urol. Nephrol. 37(3), 195-201 (2003). (Pubitemid 36791815)
10. Babjuk M, Oosterlinck W, Sylvester R et al.; European Association of Urology (EAU). EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59(6), 997-1008 (2011).
11. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66(6 Suppl. 1), 108-125 (2005). (Pubitemid 43049612)
12. van Rhijn BW, van der Kwast TH, Alkhateeb SS et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur. Urol. 61(2), 378-384 (2012).
13. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22(12), 1435-1448 (1998).
14. Burger M, van der Aa MN, van Oers JM et al. Prediction of progression of nonmuscle- invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54(4), 835-843 (2008).
15. Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscleinvasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am. J. Clin. Pathol. 133(5), 788-795 (2010).
16. May M, Brookman-Amissah S, Roigas J et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organization classifications. Eur. Urol. 57(5), 850-858 (2010).
17. Otto W, Denzinger S, Fritsche HM et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 107(3), 404-408 (2011).
18. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 164(3 Pt 1), 680-684 (2000). (Pubitemid 30637601)
19. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Huguet-Pérez J, Vicente-Rodríguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J. Urol. 164(4), 1183-1187 (2000).
20. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-465; discussion 475 (2006).
21. Lamm DL, van der Meijden PM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147(3), 596-600 (1992).
22. Chade DC, Shariat SF, Godoy G et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J. Urol. 184(1), 74-80 (2010).
23. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J. Urol. 153(3 Pt 1), 564-572 (1995).
24. Amiel GE, Shu T, Lerner SP. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr. Treat. Options Oncol. 5(5), 377-389 (2004). (Pubitemid 39481240)
25. Badalament RA, Hermansen DK, Kimmel M et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60(7), 1423-1427 (1987). (Pubitemid 17140987)
26. Talwar R, Sinha T, Karan SC et al. Voided urinary cytology in bladder cancer: is it time to review the indications? Urology 70(2), 267-271 (2007). (Pubitemid 47362257)
27. Blick CG, Nazir SA, Mallett S et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 110(1), 84-94 (2012).
28. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J. Urol. 173(4), 1108-1111 (2005). (Pubitemid 40380512)
29. Viswanath S, Zelhof B, Ho E, Sethia K, Mills R. Is routine urine cytology useful in the haematuria clinic? Ann. R. Coll. Surg. Engl. 90(2), 153-155 (2008). (Pubitemid 351447851)
30. Pegoraro C, Bondavalli C, Molani L et al. [Suprapubic bladder ultrasonography and urinary cytology: indications and limits in the follow-up of superficial bladder tumors]. Arch. Ital. Urol. Nefrol. Androl. 63(Suppl. 2), 127-129 (1991).
31. Vera-Donoso CD, Llopis B, Oliver F, Server G, Alonso M, Jimenez-Cruz JF. Follow-up of superficial bladder cancer: how to spare cystoscopies? Eur. Urol. 17(1), 17-19 (1990). (Pubitemid 20058595)
32. Stamatiou K, Moschouris H, Papadaki M, Perlepes G, Skolarikos A. Accuracy of modern ultrasonographic techniques in the follow up of patients with superficial bladder carcinoma. Med. Ultrason. 13(2), 114-119 (2011).
33. Nisman B, Yutkin V, Peretz T, Shapiro A, Barak V, Pode D. The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study. Anticancer Res. 29(10), 4281-4285 (2009).
34. Falke J, Witjes JA. Contemporary management of low-risk bladder cancer. Nat. Rev. Urol. 8(1), 42-49 (2011).
35. Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology 56(1), 37-39 (2000). (Pubitemid 30408649)
36. Hall RR, Parmar MK, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 308(6923), 257-260 (1994).
37. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4), 682-686; discussion 686 (2004).
38. Sylvester RJ, Brausi MA, Kirkels WJ et al. EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette- Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 57(5), 766-773 (2010).
39. Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette- Guérin for non-muscle-invasive bladder cancer. Eur. Urol. 56(2), 247-256 (2009).
40. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 100(1), 33-36 (2007). (Pubitemid 46878562)
41. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J. Urol. 27(3), 347-351 (2009).
42. Brausi M, Witjes JA, Lamm D et al. A review of current guidelines and best practice recommendations for the management of non-muscle-invasive bladder cancer by the International Bladder Cancer Group. J. Urol. 186(6), 2158-2167 (2011).
43. van der Meijden AP, Sylvester R, Oosterlinck W et al.; for the EAU Working Party on Non Muscle Invasive Bladder Cancer. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur. Urol. 48(3), 363-371 (2005). (Pubitemid 41188389)
44. Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6 Suppl. 1), 90-107 (2005). (Pubitemid 43049611)
45. Highshaw RA, Tanaka ST, Evans CP, deVere White RW. Is bladder biopsy necessary at three or six months post BCG therapy? Urol. Oncol. 21(3), 207-209 (2003). (Pubitemid 36723708)
46. Vukomanovic I, Colovic V, Soldatovic I, Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscleinvasive bladder cancer. Med. Oncol. 29(3), 1916-1920(2011).
47. Holmäng S, Ströck V. Should follow-up cystoscopy in bacillus Calmette-Guérintreated patients continue after five tumour-free years? Eur. Urol. 61(3), 503-507 (2012).
48. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol. 171(1), 135-138 (2004). (Pubitemid 37549108)
49. Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J. Urol. 170(1), 226-229 (2003). (Pubitemid 36734467)
50. Burger M, Zaak D, Stief CG et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur. Urol. 52(1), 142-147 (2007). (Pubitemid 46803019)
51. Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69(4), 675-679 (2007). (Pubitemid 46574917)
52. Santos Cortes JA, Gahan J, Soloway MS. Photodynamic diagnosis in urology: state of the art. Arch. Esp. Urol. 64(1), 18-31 (2011).
53. Cauberg EC, Mamoulakis C, de la Rosette JJ, de Reijke TM. Narrow band imagingassisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J. Urol. 29(4), 503-509 (2011).
54. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol. Oncol. 26(6), 646-651 (2008).
55. Daniely M, Rona R, Kaplan T et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 111(6), 517-524 (2007). (Pubitemid 350304904)
56. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 51(5), 1275-80; discussion 1280 (2007).
57. Gudjónsson S, Isfoss BL, Hansson K et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 54(2), 402-408 (2008).
58. Maffezzini M, Campodonico F, Capponi G et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 30(11), 4761-4765 (2010).
59. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can. J. Urol. 4(3), 400-405 (1997).
60. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand. J. Urol. Nephrol. 35(4), 280-282 (2001). (Pubitemid 32906848)
61. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161(5), 1486-1489 (1999). (Pubitemid 29420801)
62. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58(3), 367-371 (2001). (Pubitemid 32816352)
63. Hughes JH, Katz RL, Rodriguez- Villanueva J et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn. Cytopathol. 20(5), 285-290 (1999). (Pubitemid 29205522)
64. Miyanaga N, Akaza H, Tsukamoto T et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int. J. Urol. 6(4), 173-177 (1999). (Pubitemid 30406838)
65. Ramakumar S, Bhuiyan J, Besse JA et al. Comparison of screening methods in the detection of bladder cancer. J. Urol. 161(2), 388-394 (1999).
66. Soloway MS, Briggman V, Carpinito GA et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol. 156(2 Pt 1), 363-367 (1996). (Pubitemid 126445343)
67. Stampfer DS, Carpinito GA, Rodriguez- Villanueva J et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J. Urol. 159(2), 394-398 (1998). (Pubitemid 28049240)
68. Mansoor I, Calam RR, Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal. Quant. Cytol. Histol. 30(1), 25-32 (2008). (Pubitemid 351312097)
69. Shariat SF, Savage C, Chromecki TF et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decisioncurve analysis. Cancer 117(13), 2892-2897 (2011).
70. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271(5249), 659-662 (1996). (Pubitemid 26052913)
71. Seripa D, Parrella P, Gallucci M et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer 95(6), 364-369 (2001). (Pubitemid 33015106)
72. Baron A, Mastroeni F, Moore PS et al. Detection of bladder cancer by semiautomated microsatellite analysis of urine sediment. Adv. Clin. Path. 4(1), 19-24 (2000).
73. van der Aa MN, Zwarthoff EC, Steyerberg EW et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost- Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur. Urol. 55(3), 659-667 (2009).
74. Chung W, Bondaruk J, Jelinek J et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 20(7), 1483-1491 (2011).
75. Antony P, Rose M, Gaisa NT et al. [Characterisation of DNA methylation biomarkers for bladder cancer]. Pathologe 31(Suppl. 2), 244-250 (2010).
76. Zuiverloon TC, Beukers W, van der Keur KA et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 109(6), 941-948 (2012).
77. Friedrich MG, Toma MI, Chun JK et al. [DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder]. Urologe. A 46(7), 761-768 (2007). (Pubitemid 47047751)
78. Issaq HJ, Nativ O, Waybright T et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 179(6), 2422-2426 (2008).
79. Putluri N, Shojaie A, Vasu VT et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 71(24), 7376-7386 (2011).
80. Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. Scientific World Journal. 11, 1103-1112 (2011).
81. Mukhtar S, Perry MJ. Future prospects for bladder cancer biomarkers. BJU Int. 108(10), 1541-1543 (2011).
82. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer 69(6), 1120-1125 (1994). (Pubitemid 24161872)
83. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur. J. Cancer 29A(5), 749-753 (1993). (Pubitemid 23077059)
84. van Rhijn BW, van der Kwast TH, Liu L et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187(1), 310-314 (2012).
85. Stoeber K, Swinn R, Prevost AT et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J. Natl Cancer Inst. 94(14), 1071-1079 (2002). (Pubitemid 34830727)
86. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5(11), e13821 (2010).
87. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66(3), 543-548 (1990). (Pubitemid 20233454)
88. Cauberg EC, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJ, de Reijke TM. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur. Urol. 56(2), 287-296 (2009).
89. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66(3), 543-548 (1990). (Pubitemid 20233454)